Alector Inc.
1.63
-0.16 (-8.94%)
At close: Jan 14, 2025, 3:59 PM
1.70
4.29%
After-hours Jan 14, 2025, 07:51 PM EST
undefined%
Bid 1.6
Market Cap 159.63M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.71
PE Ratio (ttm) -0.95
Forward PE n/a
Analyst Buy
Ask 1.63
Volume 701,674
Avg. Volume (20D) 1,314,491
Open 1.82
Previous Close 1.79
Day's Range 1.61 - 1.82
52-Week Range 1.61 - 7.78
Beta undefined

About ALEC

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, incl...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 7, 2019
Employees 241
Stock Exchange NASDAQ
Ticker Symbol ALEC

Analyst Forecast

According to 5 analyst ratings, the average rating for ALEC stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 145.40% from the latest price.

Buy 60.00%
Hold 20.00%
Sell 20.00%
Stock Forecasts

Next Earnings Release

Alector Inc. is scheduled to release its earnings on Feb 25, 2025, during market hours.
Analysts project revenue of $16.80M, reflecting a 10.60% YoY growth and earnings per share of -0.61, making a 24.49% increase YoY.
1 month ago · Source
-13.1%
Alector shares are trading lower after the company... Unlock content with Pro Subscription
1 month ago · Source
-35.1%
Alector shares are trading lower after the company announced that the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in individuals with early Alzheimer's disease failed to meet its primary endpoint.